Phaseline

Companies › Nippon Shinyaku

Nippon Shinyaku: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NS-089/NCNP-02 (Brogidirsen)
Antisense oligonucleotide targeting DMD exon 45 skip
DMDPhase 2Duchenne Muscular Dystrophy (DMD)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05135663NS-089/NCNP-02 (Brogidirsen)Phase 2Duchenne Muscular Dystrophy (DMD)NeurologyApr 2027

Targets

DMD (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy

Companies built like this

NS Pharma Dyne Therapeutics MED Institute NeuroPace Sarepta Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.